Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies

Hypertension

Volumn 54, Issue 5, 2009, Pages 1084-1091

  Fagard, Robert H ^a   Celis, Hilde ^a   Thijs, Lutgarde ^a   Wouters, Stijn ^a  

^a KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

Author keywords

blocker; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Diuretic; Left ventricular mass; Meta analysis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; MIBEFRADIL; NEBIVOLOL; NIFEDIPINE; PERINDOPRIL; TELMISARTAN; VALSARTAN; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HOSPITALIZATION; MALE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70449730792     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.136655     Document Type: Article

References (89)

1. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
2. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
3. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-1513.
4. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
5. Fagard RH, Staessen JA, Thijs L. Advantages and disadvantages of the meta-analysis approach. J Hypertens. 1996;14(suppl 2):S9-S13.
6. Fagard R. Reversal of left ventricular hypertrophy. JAMA. 1996;276: 1636-1637.
7. Fagard RH. Reversibility of left ventricular hypertrophy by antihypertensive drugs. Neth J Med. 1995;47:173-179.
8. Fagard RH. A meta-analysis on comparative studies on left ventricular mass regression. Presented at the 23rd Congress of the European Society of Cardiology; September 1-5, 2001; Stockholm, Sweden.
9. Mace PJE, Littler WA, Glover DR, Rowlands DB, Stallard TJ. Regression of left ventricular hypertrophy in hypertension: comparative effects of three different drugs. J Cardiovasc Pharmacol. 1985;7(suppl 2): S52-S55.
10. Giles TD, Sander GE, Roffidal LC, Thomas MG, Given MB, Quiroz AC. Comparison of nitrendipine and hydrochlorothiazide for systemic hypertension. Am J Cardiol. 1987;60:103-106.
11. Sheiban I, Arcaro G, Covi G, Accardi R, Zenorini C, Lechi A. Regression of cardiac hypertrophy after antihypertensive therapy with nifedipine and captopril. J Cardiovasc Pharmacol. 1987;10(suppl 10):S187-S191.
12. Weiss RJ, Bent B. Diltiazem-induced left ventricular mass regression in hypertensive patients. J Clin Hypertens. 1987;3:135-143.
13. Graettinger WF, Lipson JL, Klein RC, Cheung DG, Weber MA. Comparison of antihypertensive therapies by non-invasive techniques. Chest. 1989;96:74-79.
14. Gosse P, Roudaut R, Herrero G, Dallocchio M. /3-Blockers vs angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol. 1990:16(suppl 5):S145-S150.
15. Schneeweiss A, Rosenthal J, Marmor A. Comparative evaluation of the acute and chronic effects of cilazapril and hydrochlorothiazide on diastolic cardiac function in hypertensive patients. J Hum Hypertens. 1990; 4:535-539.
16. Schulman SP, Weiss JL, Becker LC, Gottlieb SO, Woodruff KM, Weisfeldt ML, Gerstenblith G. The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med. 1990;322: 1350-1356. (Pubitemid 20154478)
17. Leonetti G, Fogari R, Mazzola C, Mangiameli S, Castello C. Comparison of the effects on blood pressure and left ventricular hypertrophy of lacidipine and hydrochlorothiazide in hypertensive patients. J Hypertens. 1991;9(suppl 3):S29-S31.
18. Wang LS, Bai MY. Comparison of the effects of nitrendipine and captopril on the regression of hypertensive left ventricular hypertrophy. Chinese Med J. 1991;104:645-648.
19. Bielen EC, Fagard RH, Lijnen PJ, Tjandra-Maga TB, Verbesselt R, Amery AK. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol. 1992;69:1200-1206.
20. Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens. 1992;10:1513-1524.
21. Gomez Pajuelo C, Gomez Sanchez MA, Delgado Jimenez JF, Fernandez Vidal P, Velasco Quintana J, Saenz de la Calzada C. Hypertensive heart disease and its evolution under antihypertensive therapy: an anatomic and functional study. Mapfre Medicina. 1992;3:233-240.
22. Otterstad JE, Froeland G, Wasenius Soeyland AK, Knutsen KM, Ekeli T. Changes in left ventricular dimensions and systolic function in 100 midly hypertensive men during one year's treatment with atenolol vs hydrochlorothiazide and amiloride (Moduretic): a double-blind, randomized study. J Intern Med. 1992;231:493-501.
23. Schulte KL, Meyer-Sabellek W, Liederwald K, van Gemmeren D, Lenz T, Gotzen R. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with per-indopril versus nifedipine. Am J Cardiol. 1992;70:468-473.
24. van Leeuwen JTM, ten Berge BS, Hamer JPM, Landsman MLJ, May JF, Smit AJ, Lie KI, Wesseling H. Comparative study of lisinopril and metoprolol in mild to moderate hypertension: antihypertensive efficacy using office, ambulatory and exercise blood pressure and effect of treatment on left ventricular mass and exercise tolerance. J Drug Dev. 1992;5:119-127.
25. Gonzalez-Fernandez RA, Altieri PI, Fernandez-Martinez J, Lugo JE. Prevalence of ventricular arrhythmias after left ventricular mass regression in the elderly. Cardiol Elderly. 1993;1:185-190.
26. Ranieri G, Taddei S, Filitti V, Andriani A, Bonfantino MV, Lamontanara G, De Cesaris R, Salvetti A. The effects of diuretic and beta-blocker treatment on cardiac and vascular structural changes in untreated essential hypertensive patients. J Hypertens. 1993;11(suppl 5):S368-S369.
27. Ribstein J, Du Cailar G, Brouard R, Mimran A. Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension. Cardiology. 1993;83(suppl 1):57-63.
28. Senior R, Imbs JL, Bory M, Amabile G, Denis B, Zannad F, De Luca N, Marchegiano R, Lahiri A, Raftery EB, Guez D, Chic M. Indapamide reduces hypertensive left ventricular hypertrophy: an international mul-ticenter study. J Cardiovasc Pharmacol. 1993;22(suppl 6):S106-S110.
29. Agabiti-Rosei E, Muiesan ML, Rizzoni D, Zulli R, Calebich S, Castellano M, Cavaliere G, Nordio G, Pasini F, Zuccato F. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol. 1994;24(suppl A):S37-S43.
30. Galderisi M, Celentano A, Garofalo M, Tammaro P, Oliviero M, Petrocelli A, De Divitiis O. Reduction of left ventricular mass by short-term antihypertensive treatment with isradipine: a double-blind comparison with enalapril. Int J Clin Pharmacol Ther. 1994;32:312-316.
31. Schiffrin EL, Yuan Deng L, Larochelle P. Effects of a /3-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
32. Trenkwalder P, Dobrindt R, Aulehner R, Lydtin H. Antihypertensive treatment with felodipine but not with a diuretic reduces episodes of myocardial ischaemia in elderly patients with hypertension. Eur Heart J. 1994;15:1673-1680.
33. Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FCP, Siu CO, Chou P, Wang SP, Chang MS. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25:1034-1041.
34. Grandi AM, Bignotti M, Gaudio G, Zanzi P, Guasti L, Venco A. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol. 1995; 26:737-741.
35. Himmelmann A, Svensson A, Dahlof B, Bergbrant A, Hansson L. Lo-sartan in essential hypertension: effects on blood pressure and left ventricular mass. High Blood Press. 1995;4:242-248.
36. Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study. Cardiovasc Drugs Ther. 1995;9:141-143.
37. van Leeuwen JTM, Smit AJ, May JF, ten Berge BS, Hamer HPM, Havinga TK, Schuurman FH, van der Veur E, Lie KI, Wesseling H. Comparative effects of diltiazem and lisinopril on left ventricular structure and filling in mild-to-moderate hypertension. J Cardiovasc Pharmacol. 1995;26:983-989.
38. Dey HM, Soufer R, Hoffer P, Wackers FJT, Black HR. Comparison of nifedipine GITS and hydrochlorothiazide in the management of elderly patients with stage I-III diastolic hypertension. Am J Hypertens. 1996;9: 589-606.
39. Shimamoto H, Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension. 1996;28: 457-463.
40. Fagard RH, Lijnen PJ. Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension. J Hypertens. 1997;15:309-317.
41. Lombardo M, Alli C, Broccolino M, Ferrari S, Montemurro L, Zaini G, Zanni D. Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension. Am Heart J. 1997;134:557-564.
42. Matsuzaki K, Mukai M, Sumimoto T, Murakami E. Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. Hypertens Res. 1997; 20:7-10.
43. Parodi O, Neglia D, Palombo C, Sambuceti G, Giorgetti A, Marabotti C, Gallopin M, Simonetti I, L'Abbate A. Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation. 1997;96:864-873.
44. Picca M, Bisceglia J, Zocca A, Pelosi G. Effects of enalapril and amlo-dipine on left ventricular hypertrophy and function in essential hypertension. Clin Drug Invest. 1997;12(suppl 1):29-35.
45. Sumimoto T, Ochi T, Ito T, Joh T, Muneta S, Hiwada K. Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility. Cardiovasc Drugs Ther. 1997;11:27-32.
46. Beltman FW, Heesen WF, Smit AJ, May JF, De Graeff PA, Havinga TK, Schuurman FH, Van der Veur E, Lie KI, Meyboom-De Jong B. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. Blood Press. 1998;7:109-117. (Pubitemid 28277476)
47. Gaudio C, Tanzilli G, Ferri FM, Villatico Campbell S, Bertocchi F, Motolese M, Campa PP. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. J Cardiovasc Pharmacol. 1998; 32:760-768.
48. Höglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins MR, Lindberg E. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology. 1998;89:263-270.
49. Manolis AJ, Beldekos D, Handanis S, Haralabidis G, Hatzissavas J, Foussas S, Cokkinos DV, Bresnahan M, Gavras I, Gavras H. Comparison of spirapril, isradipine or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. Am J Hypertens. 1998;11:640-648.
50. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass and vascular hypertrophy. Am J Hypertens. 1998;11:387-396.
51. Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, Galzerano D, Iarussi D, Iacono A. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens. 1998;12: 505-510.
52. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998;98:2037-2042.
53. Diamond JA, Gharavi A, Roychoudhury D, Machac J, Henziova MJ, Travis A, Phillips RA. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Curr Med Res Opin. 1999;15:1-8.
54. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y, de Leeuw PW, Palma-Gamiz JL, Pessina A, Motz W, Degaute JP, Chastang C; for the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus ena-lapril 20 mg: the LIVE Study. J Hypertens. 2000;18:1465-1475.
55. Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: a randomized, double-blind, controlled study of 21 obese hypertensives. Circulation. 2000;102:1802-1806.
56. Nalbantgil S, Yilmaz H, Gurun C, Ö zerkan F, Nalbantgil I, Ö nder R. Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized, double-blind study. Curr Ther Res Clin Exp. 2000;61:331-338.
57. Sihm I, Thygesen K, Krusell LR, Lederballe O. Long-term renal and cardiovascular effects of antihypertensive treatment regimens based upon isradipine, perindopril and thiazide. Blood Press. 2000;9:346-354.
58. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlöf B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized ena-lapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 2001;104:1248-1254.
59. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergren J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.
60. Malmqvist K, Kahan T, Isaksson H, Ö stergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press. 2001;10:101-110.
61. Pontremoli R, Viazzi F, Ravera M, Leoncini G, Berruti V, Bezante GP, Del Sette M, Deferrari G. Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension. J Nephrol. 2001;14:19-26.
62. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, Schuurman FH, Meyboom-De Jong B, Crijns HJGM. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19:303-309.
63. Akinboboye OO, Chou RL, Bergmann SR. Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan. J Am Coll Cardiol. 2002;40: 703-709.
64. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A; for the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002;20:2293-2300.
65. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M; for the REGAAL Study investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855-1864.
66. Rakić D, Rumboldt Z, Bagatin J, Polić S. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study. Croatian Med J. 2002;43:672-679.
67. Gaudio C, Ferri FM, Giovannini M, Pannarale G, Puddu PE, Vittore A, Fera MS, Vizza CD, Fedele F. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol. 2003;42:622-628.
68. Koldas L, Ayan F, Ikitimur B. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J. 2003;44: 693-704.
69. Sakata K, Yoshida H, Tamekiyo H, Obayashi K, Nawada R, Doi O, Mori N. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res. 2003;29:117-123.
70. Buus NH, Bøttcher M, Jørgensen CG, Christensen KL, Thygesen K, Nielsen TT, Mulvany MJ. Myocardial perfusion during long-term angio-tensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension. 2004;44:465-470.
71. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papadem-etriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation. 2004;110:1456-1462. (Pubitemid 39238023)
72. Galzerano D, Tammaro P, Cerciello A, Breglio R, Mallardo M, Lama D, Tuccillo B, Capogrosso P. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens. 2004;18:53-59.
73. Schneider MP, Klingbeil AU, Delles C, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension. 2004;44:61-66.
74. Uribe Flores JD, Hernández Jácome M, Guevara Dondé J, Segura X. Losartan versus enalapril in the reduction of left ventricular hypertrophy secondary to systemic arterial hypertension. Arch Cardiol Mex. 2004;74: 192-199.
75. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol. 2004;43:2116-2123.
76. Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, Hennig M, Baurecht H, Parati G, Mancia G, Zanchetti A; for the ELSA echocardiographic substudy group. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2005;23:1091-1098.
77. Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H. Effects of valsartan and per-indopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol. 2005;61:353-359.
78. Bilge AK, Atilgan D, Tükek T, Ozcan M, Ozben B, Koylan N, Meriç M. Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int J Clin Pract. 2005;59:306-310.
79. Fountoulaki K, Dimopoulos V, Giannakoulis J, Zintzaras E, Triposkiadis F. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am J Hypertens. 2005;18:171-177.
80. Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Capogrosso P. Three-dimensional echocardio-graphic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass: a multicenter, randomized, longitudinal study. Am J Hypertens. 2005;18:1563-1569.
81. Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R. Ventricular and vascular remodelling effects of the angio-tensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res. 2005; 33(suppl 1):39A-49A.
82. Sabharwal NK, Swinburn J, Lahiri A, Senior R. Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension. Clin Drug Investig. 2005;25:367-375.
83. Ariff B, Zambanini A, Vamadeva S, Barratt D, Xu Y, Sever P, Stanton A, Hughes A, Thom S. Candesartan-and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke. 2006;37:2381-2384.
84. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier C, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Circulation. 2006;113:1213-1225.
85. Solomon SC, Appelbaum E, Manning WJ, Verma A, Berglund T, Luka-shevich V, Cherif Papst C, Smith BA, Dahlöf B; for the ALLAY Trial investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119: 530-537.
86. Fagard RH, Staessen JA, Thijs L, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Leonetti G, Sarti C, Tuomilehto J, Webster J, Yodfat Y; for the Syst-Eur Trial Investigators. Prognostic significance of baseline electrocardiographic voltages and their serial changes in older patients with systolic hypertension. Hypertension. 2004;44: 459-464.
87. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papa-demetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment in hypertension. JAMA. 2004;292:2350-2356.
88. Carlberg B, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
89. Bradley HA, Shey Wiysonge C, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006; 24:2131-2141